Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

BACKGROUND: Avelumab, a human anti–programmed death-ligand 1 immunoglobulin G1 monoclonal antibody, showed favorable efficacy and safety in patients with metastatic Merkel cell carcinoma (mMCC) in the phase II JAVELIN Merkel 200 trial, leading to approval in multiple countries. We describe real-worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, John W, Lebbé, Celeste, Grignani, Giovanni, Nathan, Paul, Dirix, Luc, Fenig, Eyal, Ascierto, Paolo Antonio, Sandhu, Shahneen, Munhoz, Rodrigo, Benincasa, Elena, Flaskett, Sarah, Reed, Josh, Engelsberg, Arne, Hariharan, Subramanian, Kasturi, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252959/
https://www.ncbi.nlm.nih.gov/pubmed/32269140
http://dx.doi.org/10.1136/jitc-2019-000313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252959/
https://www.ncbi.nlm.nih.gov/pubmed/32269140
http://dx.doi.org/10.1136/jitc-2019-000313

Ejemplares similares